Back to Results

CryoCell International Inc (CCEL)

CryoCell International Inc. is a common stock listing on the NYSE for a healthcare company focused on cord blood and cord tissue cryopreservation services in the United States. The company provides cellular processing and cryogenic storage for families, with services centered on collecting and preserving umbilical cord blood and tissue stem cells. It also processes and stores umbilical cord blood stem cells for public use. In addition, CryoCell manufactures PrepaCyte CB processing system units and provides cold storage services to third-party pharmaceutical companies and medical institutions. The company markets its preservation services directly to expectant parents and through healthcare professionals such as obstetricians, pediatricians, childbirth educators, and certified nurse-midwives. CryoCell International was incorporated in 1989 and is headquartered in Oldsmar, Florida.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-CCEL
$3.58
3.9% Upside
Fair
—
—
—
Fair
—
—
—
17.4%
October 9, 2026
-11.3x
-1.6x
0.9x
27.8 M
33.598 M
24.4%
50.3%
-0.3
0.0%
-185.4%
Valuation • Fair Value

CryoCell International Inc (NYSE-CCEL) Fair Value by Valuation Model

Compare the primary fair value estimate for CryoCell International Inc (NYSE-CCEL) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$3.58

Estimated upside of 3.9% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$3.02

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

$5.28

Earnings power value estimate.

Comps Fair Value

$3.87

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for CryoCell International Inc (NYSE-CCEL) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for CryoCell International Inc (NYSE-CCEL)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

31.128 M

Current operating scale indicator.

Revenue Forecast

30.043 M

Forward revenue estimate.

EBITDA

871.17 K

Current operating profitability reference.

EBITDA Forecast

4.799 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review CryoCell International Inc (NYSE-CCEL) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for CryoCell International Inc (NYSE-CCEL)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

6

Mid-range quality score.

Beneish M-Score

-2.96

No elevated caution signal from this screen.

Altman Z-Score

-0.3

Lower score that deserves closer risk review.

FCF / Net Income

-185.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for CryoCell International Inc (NYSE-CCEL). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for CryoCell International Inc (NYSE-CCEL)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

October 9, 2026

Days to Earnings

80

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

17.4%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

0.0%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for CryoCell International Inc (NYSE-CCEL), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

CryoCell International Inc (NYSE-CCEL) Stock Forecast & Technical Outlook

Review CryoCell International Inc (NYSE-CCEL) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for CryoCell International Inc (NYSE-CCEL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for CryoCell International Inc (NYSE-CCEL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for CryoCell International Inc (NYSE-CCEL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Neutral

The weekly technical read for CryoCell International Inc (NYSE-CCEL) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for CryoCell International Inc (NYSE-CCEL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for CryoCell International Inc (NYSE-CCEL)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, CryoCell International Inc (NYSE-CCEL) has a Hold consensus, with 0 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 0
Hold 1
Sell 0
FAQ • Fast Investor Answers

CryoCell International Inc (NYSE-CCEL) Stock FAQ

Quick answers about CryoCell International Inc (NYSE-CCEL) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$3.58
Estimated upside 3.9%
Valuation Rating
Undervalued
Estimated upside of 3.9%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Fair
Current financial-health read

The current fair value estimate for CryoCell International Inc (NYSE-CCEL) is $3.58. This implies an estimated upside of 3.9% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 3.9% versus the current market price.

An analyst price target for CryoCell International Inc (NYSE-CCEL) is not currently available in the latest data file.

The current financial health read for CryoCell International Inc (NYSE-CCEL) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for CryoCell International Inc (NYSE-CCEL) is October 9, 2026.

Based on the current data, dividend yield is 17.4%.

The current P/E ratio listed for CryoCell International Inc (NYSE-CCEL) is -11.3x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for CryoCell International Inc is 27.8 M.

The current enterprise value listed for CryoCell International Inc is 33.598 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for CryoCell International Inc is NYSE-CCEL, and the stock is listed on NYSE.

CryoCell International Inc (NYSE-CCEL) is listed on NYSE.

The current debt-to-total-capital ratio listed for CryoCell International Inc is 24.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for CryoCell International Inc is 50.3%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Providers & Services Stocks on NYSE View more

Unitedhealth Group (UNH) Unitedhealth Group (UNH)
CVS Health Corp (CVS) CVS Health Corp (CVS)
McKesson Corporation (MCK) McKesson Corporation (MCK)
Elevance Health Inc (ELV) Elevance Health Inc (ELV)
HCA Holdings Inc (HCA) HCA Holdings Inc (HCA)
Cigna Corp (CI) Cigna Corp (CI)
Cencora Inc (COR) Cencora Inc (COR)
Cardinal Health Inc (CAH) Cardinal Health Inc (CAH)
Humana Inc (HUM) Humana Inc (HUM)
Centene Corp (CNC) Centene Corp (CNC)
Labcorp Holdings Inc (LH) Labcorp Holdings Inc (LH)
Quest Diagnostics Incorporated (DGX) Quest Diagnostics Incorporated (DGX)
Tenet Healthcare Corporation (THC) Tenet Healthcare Corporation (THC)
DaVita HealthCare Partners Inc (DVA) DaVita HealthCare Partners Inc (DVA)
Fresenius Medical Care Corporation (FMS) Fresenius Medical Care Corporation (FMS)
Molina Healthcare Inc (MOH) Molina Healthcare Inc (MOH)
Encompass Health Corp (EHC) Encompass Health Corp (EHC)
Universal Health Services Inc (UHS) Universal Health Services Inc (UHS)
Hims Hers Health Inc (HIMS) Hims Hers Health Inc (HIMS)
PACS Group Inc (PACS) PACS Group Inc (PACS)
Chemed Corp (CHE) Chemed Corp (CHE)
Hinge Health Inc (HNGE) Hinge Health Inc (HNGE)
Concentra Group Holdings Parent Inc (CON) Concentra Group Holdings Parent Inc (CON)
Brookdale Senior Living Inc (BKD) Brookdale Senior Living Inc (BKD)